2021
DOI: 10.1007/s40266-021-00841-x
|View full text |Cite
|
Sign up to set email alerts
|

Treatment of Metastatic Gastrointestinal Stromal Tumors (GIST): A Focus on Older Patients

Abstract: Gastrointestinal stromal tumors (GIST) originating in the Cajal cells are the most common mesenchymal neoplasms of the gastrointestinal tract. The median age of patients with this diagnosis is 65 years, and over 20% of cases affect people over the age of 70 years. The effectiveness and tolerability of systemic treatment with tyrosine kinase inhibitors in older patients with GIST seem to be similar to that in younger patients, but some studies have shown that treatment of older patients is suboptimal. Disabilit… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
3
1

Relationship

0
4

Authors

Journals

citations
Cited by 4 publications
(1 citation statement)
references
References 113 publications
(172 reference statements)
0
1
0
Order By: Relevance
“…In addition, frailty has a very close overlap with sarcopenia 80 . Frailty was associated with an increased risk for mortality and morbidity related to cancer and worse response to treatment 81 , therefore, this could result in decreased numbers of frail patients who received TACE, hepatectomy, or systemic treatment. This selection bias could explain why we found more impact of sarcopenia in the BCLC-0/BCLC-A groups in comparison with those treated with TACE or systemic treatment.…”
Section: Discussionmentioning
confidence: 99%
“…In addition, frailty has a very close overlap with sarcopenia 80 . Frailty was associated with an increased risk for mortality and morbidity related to cancer and worse response to treatment 81 , therefore, this could result in decreased numbers of frail patients who received TACE, hepatectomy, or systemic treatment. This selection bias could explain why we found more impact of sarcopenia in the BCLC-0/BCLC-A groups in comparison with those treated with TACE or systemic treatment.…”
Section: Discussionmentioning
confidence: 99%